• 1
    Murray CJL, Lopez DL. Global mortality, disability, and the contribution of risk factors: global burden of disease study. Lancet 1997; 349: 143642.
  • 2
    Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR. Estimates of the prevalence of selected arthritic and musculoskeletal disease in the United States. J Rheumatol 1989; 16: 42741.
  • 3
    Hawker G, Melfi C, Paul J, Green R, Bombardier C. Comparison of a generic (SF-36) and a disease specific (WOMAC) instrument in the measurement of outcomes after knee replacement surgery. J Rheumatol 1995; 22: 11936.
  • 4
    Bellamy N, Buchanan WW. A preliminary evaluation of the dimensionality and clinical importance of pain and disability in osteoarthritis of the hip and knee. Clin Rheumatol 1986; 5: 23141.
  • 5
    Wright JG, Young NL. A comparison of different indices of responsiveness. J Clin Epidemiol 1997; 50: 23946.
  • 6
    Ruof J, Shanga O, Stucki G. Comparative responsiveness of 3 functional indices in ankylosing spondylitis. J Rheumatol 1999; 26: 195963.
  • 7
    Laupacis A, Bourne R, Rorabeck C, Feeny D, Wong C, Tugwell P, et al. The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am 1993; 75: 161926.
  • 8
    Jones CA, Voaklander DC, Johnston DWC, Suarez-Almazor ME. Health related quality of life outcomes after total hip and knee arthroplasties in a community based population. J Rheumatol 2000; 27: 174552.
  • 9
    Brazier JE, Harper R, Munro J, Walters SJ, Snaith ML. Generic and condition-specific outcome measures for people with osteoarthritis of the knee. Rheumatology (Oxford) 1999; 38: 8707.
  • 10
    Dieppe P. Therapeutic targets in osteoarthritis. J Rheumatol 1995; 22 Suppl 43: 1369.
  • 11
    Bellamy N. Outcome measurement in osteoarthritis clinical trials. J Rheumatol 1995; 22 Suppl 43: 4951.
  • 12
    Lequesne M, Brandt KD, Bellamy N, Moskowitz R, Menkes CJ, Pelletier J-P. Guidelines for testing slow acting drugs in osteoarthritis. J Rheumatol 1994; 21 Suppl 41: 6573.
  • 13
    Bellamy N. WOMAC Osteoarthritis Index: a user's guide. London, Ontario, Canada: University of Western Ontario; 1995.
  • 14
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15: 183340.
  • 15
    Bellamy N. Pain assessment in osteoarthritis: experience with the WOMAC osteoarthritis index. Semin Arthritis Rheum 1989; 18 Suppl 2: 147.
  • 16
    Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Duku E. Signal measurement strategies: are they feasible and do they offer any advantage in outcome measurement in osteoarthritis? Arthritis Rheum 1990; 33: 73945.
  • 17
    Bellamy N, Kean WF, Buchanan WW, Gerecz-Simon E, Campbell J. Double blind randomized controlled trial of sodium meclofenamate (Meclomen) and diclofenac sodium (Voltaren): post validation reapplication of the WOMAC osteoarthritis index. J Rheumatol 1992; 19: 1539.
  • 18
    Stucki G, Meier D, Stucki S, Michel BA, Tyndall AG, Elke R, et al. Evaluation of a German version of the WOMAC (Western Ontario and McMaster Universities) osteoarthritis index. Z Rheumatol 1996; 55: 409.
  • 19
    Theiler R, Brooks P, Ghosh P. Clinical, biochemical and imaging methods of assessing osteoarthritis and clinical trials with agents claiming ‘chondromodulating’ activity. Osteoarthritis Cartilage 1994; 2: 123.
  • 20
    Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptional framework and item selection. Med Care 1992; 30: 47383.
  • 21
    Stucki G, Liang MH, Phillips C, Katz JN. The Short Form-36 is preferable to the SIP as a generic health status measure in patients undergoing elective total hip arthroplasty. Arthritis Care Res 1995; 8: 17481.
  • 22
    Altman RD, Bloch DA, Bole GG Jr, Brandt KD, Cooke DV, Greenwald RA, et al. Development of clinical criteria for osteoarthritis. J Rheumatol 1987; 14 (special issue): 36.
  • 23
    Altman R, Alarcón G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 50514.
  • 24
    Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990; 28: 63242.
  • 25
    Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989; 27 Suppl 3: 17889.
  • 26
    Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures: statistics and strategies for evaluation. Control Clin Trials 1991; 12 Suppl 4: 142S158S.
  • 27
    Jaeschke R, Singer J, Guyatt GH. Measurement of health status: ascertaining the minimal clinically important difference. Control Clin Trials 1989; 10: 40715.
  • 28
    Stucki G, Liang MH, Fossel AH, Katz JN. Relative responsiveness of condition-specific and generic health status measures in degenerative lumbar spinal stenosis. J Clin Epidemiol 1995; 48: 136978.
  • 29
    Stucki G, Daltroy L, Liang MH, Lipson SJ, Fossel AH, Katz JN. Measurement properties of a self-administered outcome measure in lumbar spinal stenosis. Spine 1996; 21: 796803.
  • 1
    Angst F, Aeschlimann A, Michel BA, Stucki G. Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J Rheumatol. In press.
  • 31
    Bland M. An introduction to medical statistics. Oxford (UK): Oxford Medical Publications; 1996.
  • 32
    Lasserre M, Boers M, van der Heijde D, Boonen A, Edmonds J, Saudan A, et al. Smallest detectable difference in radiological progression. J Rheumatol 1999; 26: 7319.
  • 33
    Nunnally JC, Bernstein IH. Psychometric theory. New York: McGraw-Hill; 1978.
  • 34
    Lachin JM. Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials 1981; 2: 93113.
  • 35
    Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987; 40: 1718.
  • 36
    Kastenbaum MA, Hoel DG, Bowman KO. Sample size requirements: one-way analysis of variance. Biometrika 1970; 57: 42130.
  • 37
    Rosner B. Fundamentals of biostatistics. Boston: PWS-Kent; 1990.